The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / October / Reading Skin Cancer’s Molecular Fingerprint
Oncology Technology and innovation Molecular Pathology

Reading Skin Cancer’s Molecular Fingerprint

Machine-learning models analyzed Raman spectra to distinguish cancerous tissue from normal skin

10/13/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

5 Key Takeaways
  • 1

    A handheld Raman spectroscopy system combined with machine learning to classify normal skin, basal cell carcinoma, and squamous cell carcinoma in a preliminary study.

  • 2

    The researchers analyzed almost 1,000 spectra from more than 50 removed tissue samples using a mobile system with a 785-nm laser.

  • 3

    K-nearest neighbors and support vector machine models achieved the highest overall accuracy, at approximately 84%.

  • 4

    A shallow neural network achieved 80.8% accuracy and the highest area under the receiver operating characteristic curve, at 0.910.

  • 5

    Testing involved removed tissue rather than patients, and the study’s performance remained below the researchers’ stated clinical-use targets of more than 90%.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.